No Subject Date 38 Wellmarker Bio Announced Successful First Subject Dosed in Phase I Clinical Study of WM-S1-030 for Treatment for Colorectal Cancer and Progressive ... 2021-07-20 37 Wellmarker Bio’s R&D Center Recognized for an Outstanding Research Capabilities 2021-06-29 36 Wellmarker Bio Presents Preclinical Data for WM-A1 at the AACR Annual Meeting 2021 2021-04-13 35 Wellmarker Bio Shares Mid and Long Term Goals at the Interview with the Medical News 2021-04-05 34 Wellmarker Bio Registers Phase I Study Plan at ClinicalTrials.gov 2021-03-19 33 Wellmarker Bio Signs CDMO Contract with Samsung Biologics 2021-03-16 32 Wellmarker Bio Shares its Plans on Clinical Trial at the Korean Economic Daily 2021-03-05 31 WellmarkerBio Receives Approval for Phase I Clinical Trial from the Australian Therapeutic Goods Administration 2021-03-03 30 Wellmarker Bio Introduces Medidata’s Solution to Clinical Study 2021-01-26 29 Wellmarker Bio Announces Phase I Clinical Trial Plan at the Korea Bio Investment Conference 2020 2020-12-28 1 2 3 4
